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direct interviews and auditorium/e-mail/internet/postal surveys among pharma-
cists (28/27 questions for public pharmacies (PP)/hospital pharmacies (HP) respec-
tively) and consumers (13 questions). RESULTS: The survey was conducted be-
tween May and October 2011 among PP (N958) and HP (N91). 38.1 % PP and 59.3%
HP confirmed that the level of their knowledge of PT is definitely unsatisfactory and
requires substantial broadening. The majority of pharmacists believe medicines
from PT to be as safe as other medicines (83.4 %/74.2% PP/HP respectively). Almost
40% of pharmacists agree that the introduction of PT medicines has increased
competitive pressure and contributed to a decrease in the prices of medicines
registered using other regulatory procedures. Pharmacists indicated that the most
desired solutions which would support the PT development in Poland are a nation-
wide information campaign concerning PT and training for pharmacists on the
legal and economic aspects. The survey among consumers revealed that 90% of
respondents had not ever heard about PT. 51% of consumers indicated that lower
price is the most important factor in convincing them to purchase PT medicines.
CONCLUSIONS: Pharmacists have limited knowledge about PT. There is a strong
need for training directed at pharmacists. The hospital market is still under-ex-
plored in Poland and therefore represents a very attractive opportunity for the PT
development. Only 10% of consumers are familiar with the PT concept which re-
veals the urgent need for a nationwide campaign to highlight the issue of PT.
Product price is the most important incentive for consumers that in convincing
them to purchase PT products.
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OBJECTIVES:An extensive insight into drug utilization as an economic and a public
health issue can only be obtained when related to the integrated health state of the
respective population.Our target is to investigate the utilization trends of cardio-
vascular drugs in Croatia during the period 2007- 2010, thus focusing on the most
common pharmacological/therapeutic subgroups. This allows us to make direct
comparisons with the number of patient’s hospital admissions connected to car-
diovascular events. METHODS: The data of drug utilization in Croatia is collected
and analyzed by the Croatian Agency for Medicinal Products and Medical Devices
HALMED. By applying the Anatomical-Therapeutic-Chemical methodology (ATC),
the given data is used to calculate the number of defined daily doses (DDD) and
DDD per 1000 inhabitants per day (DDD/1000/day) between 2007-2010, whereas the
data of hospital statistics is analyzed by The Public Health Institute. RESULTS: The
utilization of all cardiovascular drugs indicate an increase of 47.55% (from 248.88
DDD/1000/day in 2007 to 367.23 DDD/1000/day in 2010), while the total cost in-
creased for 13.09% (from 863,601,721 KN in 2007 to 976,657,904 KN in 2010). The
utilization of the lipid modifying agents (C10) increased the most (78.93%), followed
by agents acting on the renin-angiotensin system (57.51%) and succeeded by cal-
cium channel blockers (28.46%). The total number of hospital admissions related to
cardiovascular diseases decreased from 84,413 in 2007 to 81,575 in 2010.
CONCLUSIONS:During the period 2007-2010 the utilization of cardiovascular drugs
increased significantly. In the same period the number of hospital admissions of
the patients with main cardiovascular events (3.4%) indicated a decrease. It is
necessary to undertake further analysis of these co-founders.
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OBJECTIVES: In Malaysia public sector, medicines spending in Ministry of Health
health facilities has increased by 428% from 1998 to 2008. The ultimate aim of this
research is to examine the trend of medicine expenditure and to identify the fac-
tors associated with the changes in medicine expenditure. METHODS: This was a
cross-sectional study. It studied prescriptions from 2007 to 2009 at the Pharmacy
Department of SFMS Hospital in Johor State. Simple linear regression and multiple
linear regression analysis were conducted. RESULTS: Total medicines expendi-
tures for outpatient and inpatient rose every year. In outpatient, volume of medi-
cine utilization increased over the years. Medicine expenditure declined in 2009
despite the continuous rise of medicines utilization. Median cost per medicine
declined throughout these three years. Inpatient had a continuous rise in medicine
expenditure. Median cost per medicine was fluctuating between 2007 and 2009 and
was about 35% lower than outpatient. In outpatient, median cost per medicine was
significantly different between years 2007, 2008 and 2009 for all variables except for
hospital discipline Paediatric and X-ray. Meanwhile in inpatient, the exception was
for Dermatology, X-ray, Ophthalmology and Dental. The study found that volume
of medicine utilization, which includes the number of medicines, number of med-
icines per prescription and duration of supply, contributed significantly to the
increase of medicine expenditure. Demographics, price and new medicine ap-
proved in the formulary were found to have no impact. CONCLUSIONS: The in-
crease of medicine utilization rate could be due to the increase of population; the
increase of the elderly population and new treatment guidelines and treatment
which was previously not available. Other factors include off-label prescribing,
irrational prescribing and poly-pharmacy. These three factors can lead to medica-
tion wastage and higher cost of treatment. Duration of medicine supply must be
carefully monitored as longer duration might result in medication wastage.
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OBJECTIVES: The signing of the TRIPS agreement in 1995 and Doha Declaration in
2001 have allowed low and middle-income countries to issue compulsory licenses
(CLs) for medicines in times of national emergency. While normally for infectious
diseases, given the epidemiologic transition occurring in these countries along
with the development of insurance systems, it is likely that the trend in the next
decade will be towards a higher demand for more expensive medicines to treat
non-communicable diseases (NCDs). We sought to determine the impact of CLs for
medicines that treat NCDs and make recommendations as to how pharmaceutical
companies and governments can work together in the future. METHODS: We ana-
lysed a series of cases where a CL was issued, or the manufacturer successfully
negotiated to retain patent rights for drugs treating NCDs to determine the relative
impact of the CL or negotiations, prices were benchmarked and compared before
and after CL issuance in 2012 US dollars using the medical commodities consumer
price index and relevant exchange rates. RESULTS: Of nine CL cases identified, six
resulted in an issued license, two were withdrawn, and one was negotiated and
resulted in a discount and cost sharing agreement. For licenses issued, the average
price reduction was 86.2% and supply was issued to a generics manufacturer.
Roche recently decreased the prices of three of its products by an average of 91.0%
in India - indicating there may be a trend to reducing price in order to protect patent
rights and avoid CL issuance. CONCLUSIONS: Low-income countries are increas-
ingly using CLs to obtain lower prices for medicines to treat NCDs. Price negotiation
tended to result in a greater price decrease than issued CLs, highlighting the im-
portance placed on retaining patent rights. Pharma companies could consider pro-
actively seeking cost-sharing arrangements to provide access to low-income pa-
tients and maintain market exclusivity.
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OBJECTIVES: To investigate the horizontal equity concerning the use of primary
health care services in Greece in 2006 and in 2011. Given that the economic crisis
affects the health care system in Greece, the comparison between the findings
depicts the post-crisis effects on the use of primary health care services.
METHODS: The research is based on two cross-sectional surveys, which took place
in 2006 and in 2011, and the sample size was 4003 and 6569 respectively. Moreover,
a random, stratified sampling was applied in both cases, which took into account
the age, the gender, the urbanization rate and the geographical region. RESULTS:
The Concentration Index for the measurement of horizontal equity (CHE) can be
estimated as CU-CN. The CU index depicts the use of primary health care services,
based on the number of medical visits. Additionally, the CN index intends to specify
the use of primary health care services in terms of need for care. It is also notewor-
thy that CN was estimated after applying the Poisson Regression method (depen-
dent variable: use of primary health care services, independent variables: self as-
sessed health status and chronic health problems). According to the results, CHE
was 0.06 in 2006, as CU and CN were estimated at 0.14 and 0.08 respectively.
Furthermore, CU was0.06, while CN was estimated at0.04 in 2011. Therefore CHE
decreased to 0.02. CONCLUSIONS: The low-income individuals tend to use pri-
mary health care services more than the high-income individuals, regardless the
economic crisis. This finding can be explained, as the low income is usually accom-
panied with a lower health status. Generally, as CHE is close to zero, there are not
strong indications of inequality. However, CHE increased in 2011 (closer to zero),
which implies that the inequality shifted from higher income individuals.
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OBJECTIVES: Cancer drugs are the world’s highest selling category of therapeutic
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement of
all branded products. This study reviewed recent cancer drug reimbursement mod-
els and developed lessons and implications for future products. METHODS: Re-
viewed cancer drug reimbursement schemes in developed and emerging markets.
Interviewed payers and KOLs to develop lessons and implications for future
products. RESULTS: Public and private payers worldwide have implemented sev-
eral new models for cancer drug reimbursement to manage budgets and control
costs. In the US, private payers are piloting single source compendia and third party
protocols (eg. P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has
successfully negotiated lower price and discounts for first few cycles of therapy. In
Italy, AIFA has implemented registry based patient access for cancer drugs. In
India, several manufacturers have implemented novel pricing strategy for first few
cycles of therapy. In Germany, IQWIG has proposed to use correlations between
surrogate endpoints and patient relevant outcomes to determine value of cancer
drugs. Due to increased cost pressure on payers, such models are likely to inspire
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novel reimbursement schemes for other branded products.CONCLUSIONS:Cancer
drug reimbursement models are setting new benchmark for payers to manage
access and control costs. These models have significant implications for other
expensive branded products.
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OBJECTIVES: 1) Assess the current status of data disclosure in terms of Medicines
Registration and Quality Assurance, Availability of Medicines, Price of Medicine
and Polices and Practices concerning the promotion of medicines in Jordan; 2)
Disclose the currently available data; 3) Identify where there are gaps in
information. METHODS: Using data disclosure survey tool developed by WHO col-
laborating center in pharmaceutical policy under the Medicines Transparency In-
tiative that was implemented in Jordan(2008-2009). RESULTS: The disclosure sur-
vey results showed that only 20% of the key disclosure data around the four key
MeTA components is available and publicly disclosed, while 60% is available but
not publicly disclosed and 20% is not available. Most of the unavailable data was
related to medicines promotion and standard treatment guidelines polices and
practices. Most of polices/laws, regulations, and practices covering medicines reg-
istration, quality assurance and pricing are available, disclosed and enforcing by
law. The data disclosure process highlightined some challenges in the availability
and access to information such as limited access to some data due to requirement
of fees and limited engament of the private sector in disclosing data especially
when it comes to utilizationa nd expenditure data. CONCLUSIONS: 1) To work on
establishing a national committee with authority to monitor adherence to phar-
maceutical promotion codes of ethics; 2) To work with related parties on establish-
ing a national committee to develop evidence based standard treatment guide-
lines; 3) To work with health authorites such as the JFDA to improve accessibility to
important data such as updated medicines prices and registration status; and 4) To
establish a montoring system in collaboration with related stakholders to update
and review the disclosure status in Jordan regularly in order to monitor progress
through classifying data into A, B, and C categories A: available and publicly dis-
closed B: Available C: Not Available.
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OBJECTIVES: Since 2006, data on migration status is collected through representa-
tive survey in Chile (CASEN-survey). In this survey, around 1% reported being in-
ternational immigrants in this survey; however, 0.67% preferred not to report their
migrations status. This study aimed at exploring the living conditions and health
status of migration status missing values (MS-MV) and compare them to self-re-
ported immigrants in this survey. METHODS: Design: Cross-sectional analysis of
population-based CASEN survey-2006 in Chile (268,873 participants). This analysis
focuses on the 0.67% that did not respond the question on migration status (MS-
MV) (n1577) versus self-reported international immigrants (n1877). Six health
outcomes: any disability (dichotomous), any health problem/accident (AHPA), any
hospitalization/surgery (AHS), any chronic condition/cancer (ACCC), and any med-
ical and emergency attentions. Living conditions: Demographic factors (age, sex,
marital status, urban/rural), socioeconomic status (household income per capita,
employment status and educational level), and material standards (overcrowding,
sanitation index, housing quality standards). Weighted crude and adjusted regres-
sion models were conducted in STATA 10.0.RESULTS:The MS-MV has a higher rate
of children, especially with an ethnic background, and people living in rural set-
tings than immigrants. They show a lower SES (income, education and type of
occupation) and poorer material living conditions than immigrants. The MS-MV
show a higher rate of emergency attentions received in the past month, disability,
and AHS than immigrants. Other health events were not different between these
two population groups. CONCLUSIONS: The MS-MV represents a complex group,
affected by socioeconomic deprivation. Some of them may be undocumented im-
migrants, but there is little direct evidence to support this. Regardless of their
migration status, this is a vulnerable group that needs special consideration in
Chile. Equity-centred policy interventions in Chile should focus on improving the
living standards and protecting the health of those were categorised into this
group, particularly the children.
PHP60
ASSESSMENT OF GEOGRAPHIC PHARMACY ACCESSIBILITY IN QOM (IRAN): A
GEOGRAPHIC INFORMATION SYSTEM ANALYSIS
Kebriaee Zadeh A1, Hashemi Meshkini A2, Janghorban M3, Keshavarz K2, Nikfar S1
1Tehran University of Medical Sciences, Tehran, Tehran, Iran, 2Tehran University of Medical
Sciences, Tehran, Iran, 3Qom Provincial Center, Qom, Qom, Iran
OBJECTIVES: Accessibility to pharmacy, including geographic accessibility, is an
important goal every government tries to meet. In this study, we analyze the geo-
graphic distribution and accessibility of pharmacies in the municipal territory of
Qom (a province in Iran) for both pedestrians and drivers. METHODS: The percent-
age of households living at specific distances (150, 300, 450, 600 and 750 meters)
from one pharmacy was calculated using geographic information system (GIS)
capabilities. The analysis was performed a second time for 24-hour, 7-day phar-
macies (with 1, 2 and 3 kilometers distance) to evaluate geographic pharmacy
accessibility during holidays, on weekends, and at night. The maximum acceptable
distances for appropriate geographic pharmacy accessibility in normal days and on
holidays (and weekends) were considered 750 meters and 3 kilometers,
respectively. RESULTS: Our analysis indicated that in normal days about 88% of
households living in Qom have acceptable pedestrian accessibility, and almost all
households have acceptable driving accessibility to a pharmacy. In terms of geo-
graphic accessibility to 24-hour, 7-day pharmacies, the results showed that less
than 30% and 95% of households, have acceptable pedestrian and driver accessi-
bility, respectively. CONCLUSIONS: The geographic accessibility of pharmacies at
night and on holidays has to be addressed by provincial health policymakers. keep-
ing a pharmacy opened during holidays and at nights in the areas 24-hour, 7-day
pharmacy accessibility is poor and also offering financial incentives for pharmacies
to be established in low access areas could be considered as a short term solution.
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OBJECTIVES: To examine the relationships between urgent care activity and mor-
tality among patients admitted to hospital on weekends compared to weekdays.
METHODS: A retrospective analysis was performed of all emergency acute care
admissions in England between April 2009 and March 2011 using National Health
Service Hospital Episode Statistics data. Hospital mortality among patients admit-
ted on weekends as compared to weekdays was analysed using the following mea-
sures; (1) overall deaths; (2) deaths within and after three days of admission (3)
deaths among patients with higher risk conditions and lower risk conditions. The
higher risk conditions consisted of 103 Primary Diagnosis codes (ICD-10) which
accounted for 74% of hospital deaths in England; the remaining codes were cat-
egorised as lower risk conditions. RESULTS: There were 10,221,500 emergency hos-
pital admissions during the two-year study period; 23.8% of the patients were
admitted on weekends. A total of 391,938 patients died in hospital. Weekend ad-
mission was associated with significantly higher mortality as compared to week-
day admission (Odds Ratio 1.11, 95% CI 1.10-1.12). Mortality within three days of
admission (early deaths) was also higher for patients admitted on weekends (OR
1.16, 95%CI (1.14-1.17) and this difference persisted for both higher and lower risks
conditions. However, when early deaths were excluded from the analysis, mortal-
ity was not affected by weekend admission. CONCLUSIONS: As mortality after
three days of admission was not affected by weekend admission, it is probable that
the weekend admission effect on mortality is largely due to higher disease severity
at admission on weekends rather than a consequence of shortfalls in quality of
care on weekends as postulated in previous studies.
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OBJECTIVES: The Affordable Medicines Facility – malaria (AMFm) is a financing
mechanism designed to make artemisinin-based combination therapies (ACTs) a
more accessible treatment for malaria(Laspinall 2008). This study assessed the
deployment of ACTm in southern Ghana. METHODS: The study made a census of
functional pharmacies, licensed chemical shops and private health facilities in the
southern part of Ghana. Structured questionnaires were used to interview atten-
dants at the facilities on knowledge, availability; cost, patronage of the ACTm and
training about the program. RESULTS: Overall, 78% of the facilities stocked the
ACTm. Dome had 86.5% and Taifa, 71.1%. The cost per treatment of ACTm ranged
between GHC 1.00-6.00(0.66-3.96USD). Whilst 59.2% sold ACTm within the recom-
mended range (GHC 1.00-1.50), 40.8% sold it between GHC 2.00-6.00(1.32-3.96USD).
At Dome, cost range was GHC 1.00-6.00 with GHC 2.45(1.62USD), and 2.00(1.32USD)
as the mean and median prices. Taifa, had range GHC 1.00-4.00, with GHC 1.50 as
mean and GHC 1.70(1.12USD) as the median prices. While at Taifa 78.1% of ACTm
stocked facilities sold it between GHC 1.00-1.50, only 40.6% did so at Dome (p-value
less than 0.001). Seventy seven percent of respondents had good knowledge of the
program. The main channels of communication were audio and visual. Thirty
seven percent of respondents were trained about the program. Whilst 96.3% of the
trained stocked ACTm, 67.5% of untrained stocked the drugs (p-value  0.001).
Majority (93.3 %) of the trained preferred ACTm first choice antimalarial, to non-
ACTm, compared to 50% of untrained (p-value  0.001). Overall, 62.2% of respon-
dents reported good patronage. CONCLUSIONS: The results underscore initial ob-
servation that knowledge and availability of ACTm was poor. The ACTm though
well deployed in the southern Ghana, it is more financially accessible in Taifa than
the Dome sub-district hence, difference in patronage.
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OBJECTIVES: Estimate the effect of changes in government pricing and reimburse-
ment regulations on the Turkish pharmaceutical industry. Five different product
groups within the pharmaceutical industry between 2004 and 2011 were studied.
METHODS: Five product groups were examined: original products without gener-
ics, original products with generics, generics, 20-year-old generics, and 20-year-old
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